CAU
ATRC icon

Caxton Associates (UK)’s AtriCure ATRC Stock Holding History

Caxton Associates (UK)’s Portfolio ATRC Stock Details ATRC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,472
Closed -$299K – 754
2026
Q1 		$299K Buy
10,472
+3,587
+52% +$122K 0.01% 609
2025
Q4 		$272K Buy
+6,885
New +$252K 0.01% 639

Other funds holding ATRC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Caxton Associates (UK)'s ATRC Position: Q2 2026 in Review

Caxton Associates (UK) sold out of AtriCure (ATRC) in Q2 2026, closing a stake of 10,472 shares — an estimated $299K sold.

Caxton Associates (UK) first reported a position in ATRC in Q4 2025 and held it in 2 quarters. The position peaked at $299K in Q1 2026. 252 funds tracked by Wall St. Rank hold ATRC as of Q2 2026.

  • Caxton Associates (UK) reported no remaining AtriCure position as of Q2 2026 after selling out during the quarter.
  • Caxton Associates (UK) sold 10,472 AtriCure shares in Q2 2026, an estimated $299K.
  • Caxton Associates (UK) first reported a position in AtriCure in Q4 2025 and held it in 2 quarters.
  • Caxton Associates (UK)'s AtriCure position peaked at $299K in Q1 2026.
  • 252 funds tracked by Wall St. Rank held AtriCure as of Q2 2026.

Based on Caxton Associates (UK)'s 13F filing for Q2 2026, filed 14 Aug 2026.